Lessons learnt from a discontinued randomised controlled trial:Adalimumab injection compared with placebo for patients receiving physiotherapy treatment for sciatica (Subcutaneous Injection of Adalimumab Trial compared with Control: SCIATiC) by Williams, Nefyn et al.
  
 
P
R
IF
Y
S
G
O
L
 B
A
N
G
O
R
 /
 B
A
N
G
O
R
 U
N
IV
E
R
S
IT
Y
 
 
Lessons learnt from a discontinued randomised controlled trial
Williams, Nefyn; Jenkins, Alison; Goulden, Nia; Hoare, Zoe; Hughes, Dyfrig;
Wood, Eifiona; Foster, Nadine E; Walsh, David A; Carnes, Dawn; Sparkes,
Valerie; Hay, Elaine M; Isaacs, John; Konstantinou, Kika; Morrissey, Dylan;
Karppinen, Jaro; Genevay, Stephane; Wilkinson, Clare
Trials
DOI:
10.1186/s13063-018-2801-6
Published: 31/07/2018
Peer reviewed version
Cyswllt i'r cyhoeddiad / Link to publication
Dyfyniad o'r fersiwn a gyhoeddwyd / Citation for published version (APA):
Williams, N., Jenkins, A., Goulden, N., Hoare, Z., Hughes, D., Wood, E., ... Wilkinson, C. (2018).
Lessons learnt from a discontinued randomised controlled trial: Adalimumab injection compared
with placebo for patients receiving physiotherapy treatment for sciatica (Subcutaneous Injection
of Adalimumab Trial compared with Control: SCIATiC). Trials, 19, [408].
https://doi.org/10.1186/s13063-018-2801-6
Hawliau Cyffredinol / General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or
other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal
requirements associated with these rights.
            • Users may download and print one copy of any publication from the public portal for the purpose of private
study or research.
            • You may not further distribute the material or use it for any profit-making activity or commercial gain
            • You may freely distribute the URL identifying the publication in the public portal ?
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to
the work immediately and investigate your claim.
 22. Jun. 2020
 
  Page 1 of 41 
Lessons learnt from a discontinued randomised controlled trial: Adalimumab injection 
compared with placebo for patients receiving physiotherapy treatment for sciatica 
(Subcutaneous Injection of Adalimumab Trial compared with Control: SCIATiC). 
Nefyn H Williams Department of Health Services Research, University of Liverpool, UK  
   e-mail: nefyn.williams@liverpool.ac.uk Corresponding author 
Alison Jenkins  School of Healthcare Sciences, Bangor University, UK  
   e-mail: a.jenkins@bangor.ac.uk  
Nia Goulden  School of Healthcare Sciences, Bangor University, UK  
   e-mail: n.goulden@bangor.ac.uk  
 Zoe Hoare  School of Healthcare Sciences, Bangor University, UK   
   e-mail: z.hoare@bangor.ac.uk  
Dyfrig A Hughes School of Healthcare Sciences, Bangor University, UK  
   e-mail: d.a.hughes@bangor.ac.uk  
Eifiona Wood  School of Healthcare Sciences, Bangor University, UK  
   e-mail: e.wood@bangor.ac.uk  
Nadine E Foster Arthritis Research UK Primary Care Centre, Research Institute for 
Primary Care and Health Sciences, Keele University, UK 
 e-mail: n.foster@keele.ac.uk  
 
  Page 2 of 41 
David A Walsh Arthritis Research UK Pain Centre and National Institute for Health 
Research Nottingham Biomedical Research Centre, School of 
Medicine,  University of Nottingham, UK 
 e-mail: david.walsh@nottingham.ac.uk  
Dawn Carnes Centre for Primary Care and Public Health, Barts and the London 
School of Medicine and Dentistry, UK 
 e-mail: d.carnes@qmul.ac.uk  
Valerie Sparkes School of Healthcare Science, Cardiff University, UK  
   e-mail: sparkesv@cardiff.ac.uk  
Elaine M Hay Arthritis Research UK Primary Care Centre, Research Institute for 
Primary Care and Health Sciences, Keele University, UK 
 e-mail: e.m.hay@keele.ac.uk  
John Isaacs National Institute for Health Research Newcastle Biomedical Research 
Centre, Newcastle upon Tyne Hospitals NHS Foundation Trust and 
Newcastle University, UK 
 e-mail: john.isaacs@ncl.ac.uk 
Kika Konstantinou Arthritis Research UK Primary Care Centre, Research Institute for 
Primary Care and Health Sciences, Keele University, UK 
 e-mail: k.konstantinou@keele.ac.uk  
 
  Page 3 of 41 
Dylan Morrissey Centre for Sports and Exercise Medicine, William Harvey Research 
Institute, Bart's and the London School of Medicine and Dentistry, 
Queen Mary University of London UK 
 e-mail: d.morrissey@qmul.ac.uk  
Jaro Karppinen Medical Research Centre Oulu, University of Oulu and Oulu University 
Hospital, Finland  
   e-mail: Jaro.Karppinen@ttl.fi  
Stephane Genevay University Hospitals of Geneva, Switzerland 
   e-mail: Stephane.Genevay@hcuge.ch  
Clare Wilkinson School of Healthcare Sciences, Bangor University, UK  
   e-mail: c.wilkinson@bangor.ac.uk  
Corresponding author:  
Professor Nefyn H Williams, Department of Health Services Research, Waterhouse Block B, 1-5 
Brownlow Street, Liverpool L69 3GL 
Tel: +44 (0)151 795 5305   e-mail: nefyn.williams@liverpool.ac.uk 
 
Word count 3917 
 
  
 
  Page 4 of 41 
Abstract (347 words) 
Background: Adalimumab, a biological treatment targeting Tumour Necrosis Factor alpha, 
might be useful in sciatica. This paper describes the challenges when developing a new 
treatment pathway for a randomised controlled trial of adalimumab for people with sciatica, 
and the reasons why the trial was stopped early.  
Methods: Pragmatic, parallel group, randomised controlled trial with blinded (masked) 
participants, clinicians, outcome assessment and statistical analysis in six UK sites.  
Participants were identified and recruited from general practices, musculoskeletal services 
and out-patient physiotherapy clinics. They were adults with persistent symptoms of sciatica 
of one to six months duration, with moderate to high level of disability. Eligibility was 
assessed by research physiotherapists according to clinical criteria and participants were 
randomised to receive two doses of adalimumab (80mg then 40mg two weeks later) or 
saline placebo sub-cutaneous injections in the posterior lateral thigh. Both groups were 
referred for a course of physiotherapy.  
Outcomes were measured at baseline, six weeks, six months and 12 months’ follow-up. The 
main outcome measure was the disability measured using the Oswestry Disability Index. The 
planned sample size was 332 with the first 50 in an internal pilot phase.  
Results: The internal pilot phase was discontinued after 10 months from opening due to low 
recruitment (two of the six sites active, eight participants recruited). There were several 
challenges: contractual delays, one site did not complete contract negotiations and two 
sites signed contracts shortly before trial closure; site withdrawal due to patient safety 
concerns; difficulties obtaining excess treatment costs; and in the two sites that did recruit, 
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recruitment was slower than planned due to operational issues and low uptake by potential 
partcipants.  
Conclusion:  Improved patient care requires robust clinical research within contexts in 
which treatments can realistically be provided. Step changes in treatment, such as the 
introduction of biologic treatments for severe sciatica, raise complex issues that can delay 
trial initiation and retard recruitment. Additional preparatory work might be required 
before testing novel treatments.  A randomised controlled trial of TNF alpha blockade is still 
needed to determine its cost effectiveness in severe sciatica. 
 Trial registration: Current Controlled Trials ISRCTN14569274. Registered 15 December 
2014, http://www.isrctn.com/ISRCTN14569274 
Key words: feasibility, randomised controlled trial, economic evaluation, sciatica, 
adalimumab, anti TNF-alpha, biological agents 
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Background  
Sciatica is a well-localised leg pain, attributed to nerve root irritation, that approximates to 
the dermatomal distribution of the sciatic nerve down the posterior lateral aspect of the leg 
[1]. It is a common cause of pain and disability [2]. Although most cases resolve, up to 30% 
might have persistent troublesome symptoms after one year [3,4]. Many patients whose 
symptoms settle, relapse again later [5]. Typical care pathways in the National Health 
Service (NHS) involve analgesia prescribed by a general practitioner, referral for 
physiotherapy [6,7], followed by more invasive treatment such as epidural corticosteroid 
injection or disc surgery, if symptoms persist [3,4,8]. However, the evidence for most of the 
non-surgical treatments is weak [9]; new treatment strategies are needed.  
 
Sciatica caused by lumbar nerve root pain usually arises from a prolapsed intervertebral disc 
[3], which can compress the nerve root [10], but also releases  pro-inflammatory factors 
such as tumour necrosis factor-alpha (TNF-alpha) that may lead to nerve sensitisation 
[11,12]. Biological agents such as the monoclonal antibody adalimumab bind specifically to 
TNF-alpha receptors and might have beneficial effects on the inflamed nerve root in sciatica 
[13]. Two separate network meta-analyses of different treatment strategies for sciatica 
found that biological agents had the highest probability of having the best outcomes for 
pain, but with wide confidence intervals [14,15]. A meta-analysis of biological agents for 
sciatica found insufficient evidence to change practice, but sufficient evidence to suggest 
that clinically important benefit was possible, and that a definitive RCT was warranted [16].   
 
Sciatica is costly to society [17] and although biological agents are expensive, they may be 
cost-effective if they reduce the need for more expensive treatments such as disc surgery. 
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Also as patents expire, cheaper biosimilar drugs are becoming available [18]. Adalimumab is 
a TNF-alpha blocking antibody that is administered by sub-cutaneous injection, with two 
doses given two weeks apart and should inhibit TNF-alpha for at least four weeks. 
Adalimumab dosing for psoriasis or Crohn's disease uses 80mg followed by 40mg 
subcutaneous injections [19]; the same dosing strategy is proposed in sciatica. 
 
Objective 
The aims of the RCT were to evaluate the effectiveness and cost-effectiveness of injections 
of adalimumab plus physiotherapy compared with placebo injection of 0.9% sodium 
chloride plus physiotherapy for patients with sciatica who had failed first line primary care 
treatment. However, the RCT was discontinued because of lack of progress. The aim of this 
paper is to explore the reasons for this and make recommendations to inform other 
researchers. 
 
Methods 
This was designed as a pragmatic, multi-centre, RCT with blinded (masked) participants, 
clinicians, outcome assessment and statistical analysis, with concurrent economic 
evaluation and internal pilot. The Wales Research Ethics Committee (REC) 3 granted 
approval on 27/05/2015 (15/WA/105), and clinical trial authorisation from the Medicines 
and Healthcare products Regulatory Agency (MHRA) was granted on 15/04/2015 
(21996/0002/001-0001). The setting was the NHS in England and Wales, with five 
collaborating university centres (1-5). We aimed to recruit from six NHS sites overseen by 
these five centres (A-F). Each collaborating centre would oversee a number of patient 
 
  Page 8 of 41 
identification centres which consisted of general medical practices, local musculoskeletal 
services and out-patient physiotherapy clinics.  Patients were identified in three ways:  
 By their general practitioner (GP)  
 Following a search of the general practice patient record database 
 After referral to local musculoskeletal services 
Patients were invited to participate by letter. Those who were interested were contacted by 
telephone for pre-screening and if they fitted the inclusion criteria, they were given an 
appointment in a research clinic run by a research physiotherapist. At this research clinic all 
potential participants were screened by the research physiotherapist for eligibility. If 
eligible, participants had blood tests, tuberculosis (TB) screening, biological agents 
counselling, and magnetic resonance imaging (MRI) to exclude serious spinal pathology. If 
they were still eligible, at a second screening assessment 2-3 weeks later, informed consent 
was obtained for trial entry and randomisation (Figure 1). 
Inclusion criteria 
 Clinical features of sciatica  
o Leg pain worse or as bad as back pain 
o Unilateral leg pain approximating a dermatomal distribution  
o Positive neural tension test such as straight leg raise test (SLR) restricted <50 
degrees by leg pain, or positive femoral stretch test, or muscle weakness, or 
loss of tendon reflex, or loss of sensation in a dermatomal distribution 
 18 years of age and older 
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 Persistent symptoms for at least four weeks and less than six months  
 Moderate to high severity (≥30) on Oswestry Disability Index 
Exclusion criteria 
 Unable to have MRI 
 Serious pathology 
 Neurological deficit requiring urgent spinal surgery assessment  
 Contralateral leg pain extending below the inferior gluteal margin 
 Widespread pain throughout the body  
 Prior use of biological agents within previous six months 
 Previous lumbar spinal surgery 
 Contra-indications to adalimumab injection  
 Unable to give informed consent 
Randomisation 
Secure web-based randomisation was performed using a dynamic adaptive randomisation 
algorithm [20] to protect against subversion, while ensuring that the trial maintained good 
balance to the allocation ratio of 1:1 both within each stratification variable and across the 
trial. Participants were stratified by: (1) treatment centre and (2) presence of neurological 
signs (motor weakness or sensory loss).  
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Interventions 
All participants were randomised to receive 80mg adalimumab sub-cutaneous injection 
followed two weeks later by 40mg in the posterior thigh, or an equivalent volume of 0.9% 
sodium chloride. Both groups received a concurrent course of physiotherapy over a period 
of 12 weeks [21,22].  
Internal pilot trial phase 
This aimed to assess the feasibility of the trial procedures, recruitment and retention rates, 
based on the first 50 participants recruited. The stopping criteria at the end of this internal 
pilot were: recruitment which failed to reach 80% of the planned recruitment rate target, 
drop outs exceeding 20%, or more than one centre failing to commence recruitment.  
Outcome measures  
The baseline questionnaire was administered by research physiotherapists. We planned to 
send postal questionnaires at six weeks, six and 12 months post-randomisation. The primary 
clinical outcome was back pain-related disability using the Oswestry Disability Index (ODI) 
[23] measured at 12 months, which has evidence of validity for sciatica as well as back pain. 
The primary economic outcome was Quality Adjusted Life Year (QALY) calculated from the 
EuroQol EQ-5D-5L [24].  
Condition specific outcomes 
 Oswestry Disability Index [23]  
 Leg pain version of the Roland–Morris Disability Questionnaire [25,26] 
 Sciatica Bothersomeness Index [27] 
 Pain location using a pain manikin [28] 
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Generic outcomes 
 EuroQol EQ-5D-5L [24] 
 Global assessment of change since baseline  
Psychological outcome 
 Hospital Anxiety and Depression Scale [29] 
Use of health care and social care services 
 Resource Use Questionnaire [30,31] 
Process Measures (potential predictors and mediators of outcome) 
 STarT Back risk screening tool [32] 
 Pain trajectory (based on a single question) [33] 
 Pain self-efficacy questionnaire [34] 
 Tampa Scale of Kinesiophobia [35] 
Sample size 
In order to detect an effect size of 0.4 with 90% power, 5% significance and 80% retention 
rate, 332 patients would have needed to be recruited.  
Written qualitative comments 
After the trial funding was withdrawn because of slow progress, the trial management team 
and all sites were asked to reflect on what worked and what did not work within the trial. 
Written comments were collated by the trial manager (AJ) and the chief investigator (NHW) 
and grouped into themes. 
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Results 
Trial progress 
Trial progress is compared with what was planned in Figure 2. The letter of notification of 
funding was received on 11th August 2014. The trial documentation for the regulatory 
approval was in place in December 2014. Regulatory approval was obtained from the MHRA 
on 15th April 2015 and the REC on 27th May 2015. There were long delays in signing 
contracts with University 4 and NHS sites D and E, and contracts were never signed with 
University 5 and NHS site F (Table 1). There were delays obtaining the excess treatment 
costs for some sites in England. University 3 and NHS site C withdrew from the trial in 
February 2016. The trial initially opened to recruitment on 8th December 2015 at NHS sites A 
and B, with sites D and E opening to recruitment on 11th August 2016. The trial was closed 
early on 23rd September 2016 due to poor recruitment. 
Contracting  
The main contract was between the funder (NIHR Health Technology Assessment) and 
University 1 which was one of the centres, and also acted as sponsor. Sub-contracts 
between University 1 and the participating centres and sites concerning roles and 
responsibilities and the available funding were a major issue. Initial sub-contract templates 
were drafted in November 2014, but could not proceed further until the main contract and 
finances were agreed with the funder in February 2015. Draft sub-contracts were sent to 
the relevant parties from University 1 contracts department on 31st March 2015. The time 
taken to sign contracts is shown in Table 1.  
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There were protracted discussions about the nature and content of the sub-contracts, and 
division of responsibilities between the academic partners and the NHS sites.  In the final 
adopted model, the sub-contracts were between the NHS sites and the sponsor, with 
universities providing academic support rather than taking on contractual responsibilities 
[36].  
There were initial discussions about whether to have a tripartite sub-contract between 
University 1, 4 and NHS site D, but after further discussion it was agreed that University 1 
would have separate sub-contracts. In addition, physiotherapy services were provided by 
two NHS sites and separate sub-contracts were needed for each. Two clinical rheumatology 
services were being merged during the trial set-up. The Clinical Trials Unit at University 4 
had recently had a MHRA inspection in autumn 2015, and the learning from that recent 
inspection led to further discussions concerning sponsorship arrangements, delegated 
duties and the wording of the contract to clarify the role of the NHS sites, which resulted in 
further delay. 
There remained several unresolved issues with University 5, who initially wanted a tripartite 
sub-contract between them, University 1 and NHS site F, but who later wanted to use the 
Brunswick research collaboration agreement instead [37].  In addition, MRI was to be 
undertaken by University 5, but because funding was allocated to the university rather than 
the NHS site, only 80% of the cost would be re-imbursed, and who should pay for this 
underspend was left unresolved.  
The funder also requested oversight of all the sub-contracts before they were signed. Delays 
with the sub-contracts led to delays with recruitment and retention of staff at the trial sites.  
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Excess treatment costs  
In the UK the costs of a pharmacological treatment in a RCT are met by a participating 
pharmaceutical company, or by the participating NHS organisation, and not by the research 
funder. These excess treatment costs (ETC) amounted to more than £1,000 per participant 
in the intervention group. In Wales ETCs are managed centrally and were agreed by the 
Welsh Government for the two Welsh sites (A and F), whereas in England individual NHS 
sites are responsible. An ETC application was submitted to NHS site B in June 2014, and 
approved on 11th March 2015. In NHS site D an initial application for ETC was declined due 
to insufficient funds. The co-investigators from University 4 led negotiations with both NHS 
site D and the local Clinical Commissioning Groups (CCGs). Both parties argued that they 
were not funded to support these ETCs, despite guidance on attributing the costs of health 
and social care research and development (AcoRD) [38]. Following negotiation it was agreed 
that the costs would be split between the local CCGs and the charitable funds from NHS site 
D. ETCs were approved for NHS site D on 19th August 2015. Provisional ETCs were agreed for 
NHS site C, who were told that it would be finalised once research and development 
approval was given. 
Withdrawal of site 
Eight months after their initiation NHS site C reviewed the risk assessment of the trial. The 
locality has a high incidence of TB and there had recently been several difficult and complex 
cases treated locally, which had drawn the attention of the local press and community 
pressure groups [39,40]. Adalimumab is known to re-activate latent TB [19] and all patients 
should be evaluated for TB before commencing treatment. The principal investigator (PI) 
was worried about the risk of re-activating TB with the initial 80mg dose of adalimumab, 
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and decided to withdraw from the trial. Consequently University 3 also withdrew from the 
trial. This withdrawal led to a risk review for the other sites, who concluded that available 
data indicated an acceptable risk of infection in their populations, which was consistent with 
advice provided in the Patient Information Sheet. 
Research physiotherapist recruitment 
Delays in signing sub-contracts and setting up sites led to delays in recruiting the research 
physiotherapists at study sites. In NHS site A a physiotherapist was seconded from the NHS 
physiotherapy department, but was required to return to clinical duties because of staffing 
shortages. This led to delays in recruiting participants into the trial, and the loss of potential 
participants. The availability of research nurses and consultant rheumatologists was limited 
due to other clinical commitments, so co-ordination of biological agent counselling and 
investigations were difficult within the time available.  
Trial recruitment 
Recruitment data for the trial are presented in Figure 3 and reasons for withdrawal or 
exclusion in Table 2. NHS sites A and B recruited from December 2015 to September 2016. 
NHS sites D and E recruited from August to September 2016.  
Recruitment was lower than anticipated.  Invitation letters were sent to 1,546 potential 
participants across sites A and B, 583 (38%) were interested in participating and underwent 
pre-screening by telephone. At pre-screening 210 (36%) did not have sciatica according to 
our criteria and 173 (30%) had symptoms for longer than six months, making them ineligible 
for the trial. Twenty five (4.3%) attended for screening at the first clinic assessment, 13 
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(52%) were eligible after the second clinical assessment and eight were randomised. The 
other five were eligible but could not be randomised due to study closure. 
In NHS site A, 16 GP practices identified eligible patients presenting to the practice using 
database searches or opportunistic referral. Musculoskeletal clinics and physiotherapy 
departments also searched for eligible patients presenting to their clinics.  
NHS site B mainly recruited from a secondary care back pain service rather than from 
primary care, and had a higher rate of exclusion because of longer duration of symptoms 
(19% of those excluded) than the other sites (NHS site A 4%, NHS sites D and E 5%).  It was 
noted by the PI at this site that referrals of sciatica patients to the clinics had reduced 
between planning stages and the start of  trial recruitment, due to a change in the referral 
pathway commissioned by the local CCG. Therefore, the planned recruitment pathway was 
changed to inviting GP practices to identify eligible patients by database search or 
opportunistic referral, independent of referral to specialist services. Database searches 
commenced at 12 practices in June 2016, 756 potential participants were identified by GP 
practices, 11 were invited to first clinical assessment screening, and five provided initial 
consent to participate before the trial was terminated. 
NHS sites D and E had opened to recruitment on 11th August 2016, but the trial was closed 
on 26th September 2016. During this period there was a reasonable response rate of 14 out 
of 43 invitations to participate and nearly half of these, six out of 14, were from GPs handing 
out trial information packs during primary care consultations. This method of recruitment 
could have been more successful, but we were unable to test this properly before the trial 
closed. One patient who was eligible, after assessment by the research physiotherapist, was 
not able to participate because of trial closure. 
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Adverse events 
No adverse events or adverse reactions were recorded for any of the eight participants. 
 
Discussion 
Summary of lessons learnt 
This study has several important findings with major implications for developing evidence, 
within a UK setting, for challenging, expensive interventions with the potential for rare but 
significant side-effects. We found that treatment pathways for acute sciatica varied across 
research sites, and changed during the study period. This necessitated a flexible and 
heterogenous approach to study recruitment, matching local treatment pathways. It was 
possible to introduce a novel treatment approach (biologic therapy) requiring specialist 
services (rheumatology), not normally a part of existing treatment pathways, within the 
context of a clinical trial. However, delivering this RCT was challenging, involving multiple 
professional groups across different healthcare organisations. In the future, additional 
feasibility studies, more efficient site set-up, improved and pilot tested recruitment 
methods and longer recruitment periods might be appropriate. 
There were four main factors that led to delays and early trial closure: contracting issues; 
securing the payment of ETCs; site withdrawal due to concerns about re-activating TB in a 
highly prevalent area; and a complex trial recruitment process that did not always match 
local care pathways.  
There were long delays agreeing and exchanging sub-contracts with participating centres 
and sites, and contractual discussions with one site were never concluded. Earlier 
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agreement between sponsor, university centres and NHS sites might have been facilitated 
by the use of model agreements such as the Brunswick research collaboration agreement 
[37]; site feasibility questionnaires; or research infrastructure that could facilitate the 
contracting process in multi-site research, such as the National Institute of Health Research 
Translational Research Partnership [41]. 
Negotiations for the ETCs were protracted in England, where responsibility for these costs 
had to be negotiated with different NHS organisations with competing cost pressures; new 
arrangements are needed [42].  
One site withdrew from the RCT, before starting recruitment, because of a change in the PI’s 
perception of acceptable risk in the local population, fuelled by recent high-profile media 
cases. Further discussions between the Trial Management Group and the local PI around 
potential risks, related concerns and the degree of equipoise might have prevented site 
withdrawal. 
During trial set up new national management guidance was published [6] as well as a new 
national back pain and radicular pain pathway [7]. In one site the local sciatica management 
pathway changed around the time that it opened to recruitment. This site initially only 
relied on referrals to its secondary care musculoskeletal service, but later involved the 
primary care research network, which was starting to identify participants just before trial 
closure. In the other open site there were operational issues identifying the research 
physiotherapist resource, and fitting the trial around the clinical commitments of 
participating clinicians.  
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The main method for identifying participants was retrospective GP record review, but this 
had a low rate of response with only a small proportion seen at the screening assessment. 
We had modelled the numbers of eligible participants for our recruitment projections on 
the previous Assessment and Treatment of Leg pain Associated with the Spine (ATLAS) 
cohort study, which identified patients in real-time as they were consulting, with 
retrospective record review only used as a back-up [43].  Although we identified large 
numbers of potential participants, only small numbers returned reply slips indicating a 
willingness to participate. It is not known why potentially eligible participants did not wish 
to participate. Informal feedback suggested that some patients might have been much 
improved by the time they were contacted about the trial, some might have found the trial 
procedures too burdensome, such as the complex two-stage recruitment process, whilst 
others might not have wished to participate in a RCT, especially in a clinical trial of an 
investigational medicinal product (CTIMP) involving a medication with significant potential 
adverse effects. Greater patient and public involvement could offer insights into how to 
explore this. Two of the clinical sites were going to recruit participants using the same 
methods as the ATLAS cohort, which have been successfully used in another RCT of a 
primary care delivered treatment for sciatica [44]. However, these two sites signed their 
contracts just prior to trial closure. Although potential participants had started to be 
identified, there was insufficient time to recruit them.  
The current management of RCTs within the UK has emphasised recruitment efficiency and 
delivery of outcomes within short timelines [45]. This remains appropriate for treatments 
that fit within existing treatment pathways; when they do not, a new pathway must be 
developed specifically for the trial. In the current study we introduced medical screening 
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and biologic therapy administration, delivered through experienced secondary care 
rheumatology services. The heterogeneity of existing clinical pathways for sciatica (in 
primary and in secondary care) necessitated a multifaceted approach, with different 
solutions for different sites, requiring flexibility when pathways at single sites changed 
between the planning and execution of the trial.  
Comparison with previous literature 
The previous systematic review of biological agents for sciatica found a small number of 
RCTs and other studies with small numbers recruited [17]. Many of these studies also had 
poor rates of recruitment, both in the UK NHS [46] and elsewhere in Europe [47]. 
Slow or inadequate recruitment to publicly funded multicentre RCTs is still a common 
problem [48]. Systematic reviews of RCTs, that compared methods to increase trial 
recruitment, found that effective interventions included: telephone or text reminders two 
weeks after receiving their letter of invitation; the use of lay advocates who were already 
involved in the study; monetary incentives; and non-blinding of trial participants. The 
evaluation of recruitment strategies within RCTs was advocated [49,50]. Results of a 
systematic review concerning the recruitment activity of clinicians in RCTs include: the use 
of qualitative research to identify and overcome recruitment barriers, reduction of clinical 
workload associated with participation in RCTs, extra training and protected research time 
[51].   
Implications for future research 
We make a number of recommendations for future researchers (Box 1). A number of these 
are pertinent to all RCTs conducted in the UK. For example, we would recommend full 
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discussions between the sponsor’s contracting department and all university centres and 
NHS sites to obtain an early agreement about what the contracts need to include, and how 
the contracting process should be arranged, so that the university centres and the NHS sites 
have a clear understanding of their delegated roles and tasks. This may involve model 
contracts such as the Brunswick research collaboration agreements, which have been 
designed to be suitable for the majority of cases where two or more universities receive a 
joint research grant [40].  Early discussions about site requirements, perhaps using a site 
feasibility questionnaire, early dialogue with sites’ research and development departments 
and the early appointment of research staff in each site would facilitate trial set-up.  
We also make recommendations pertinent to the circumstances of this particular RCT. The 
impact of research staff shortages, in this case a research physiotherapist at one site, could 
be avoided by having dedicated research staff. In addition, involvement of the research staff 
during the initial planning stage would have been useful for planning the recruitment 
strategy. 
Further qualitative research is needed to identify reasons for low recruitment rates, using 
methods such as the QuinteT recruitment intervention, which uses a combination of 
standard and innovative qualitative research methods, with some simple quantification, to 
understand recruitment and identify sources of difficulty [52]. Possible reasons for poor 
recruitment include: concerns about the nature of the trial intervention and its side-effects; 
perceived burden of trial participation; natural history of recovery of severe sciatica; 
perceptions about the nature of sciatica itself, and whether the treatment under study is 
consistent with these. People who believe that their sciatica will resolve quickly (either 
spontaneously or with treatment) are unlikely to commit to a trial of medical intervention 
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with long follow up, particularly if they perceive that it would not provide (and might delay) 
definitive treatment. Such beliefs in the study population might not be well-founded in 
evidence, and pre-recruitment education might be necessary to help potential participants 
appreciate the possible benefits that might be achieved from novel interventions that are 
being investigated. 
Patient recruitment from ‘real’ time GP consultations, may have reduced the delays 
associated with retrospective checks of GP consulations and from referrals to physiotherapy 
and secondary care settings. Unfortunately, because of delays in agreeing ETCs, and 
finalising contracts, there was insufficient time to recruit any participants using this method 
before trial closure.  
Conclusions 
 A trial of biological therapy in patients with sciatica still needs to be performed, but would 
require a clearer contracting process, qualitative research to ensure that patients (and 
clinicians) would be willing to participate, and more efficient recruitment methods, with the 
least possible burden on patients. 
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Table 1 Time taken to sign sub-contracts 
University or NHS Site Date sub-contract 
signed 
Time to sign 
in days 
NHS Site A 8th April 2015 9 
University 2 7th July 2016 378 
NHS Site B 20th October 2015 197 
University 3 24th July 2015 115 
NHS Site C 14th August 2015 131 
University 4 2nd June 2016 427 
NHS Site D 7th July 2016 459 
NHS Site E 7th July 2016 459 
University 5 Never signed >550 
NHS Site F Never signed >550 
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Table 2 Reasons for withdrawal and exclusion for patients in NHS sites A, B, D and E 
Reasons for withdrawal and exclusion from 
invitation to first clinical assessment 
1520 
Did not confirm interest 963 
No sciatica 210 
Symptoms persisting for longer than six 
months 
173 
Widespread pain throughout body 25 
No response or no longer interested  23 
No leg pain 20 
Complicated symptoms 18 
Previous lumbar spinal surgery 16 
Trial closed early to recruitment 14 
Previous surgery 11 
Symptoms resolved/improved 10 
Pain in both legs 7 
Contra-indications to MRI 6 
Expressed interest but delay in tele-screening 
due to site staffing issues means no longer 
meet criteria for inclusion (e.g. no longer in 
pain or have recently breached the >22week 
exclusion window since replying) 
6 
Serious spinal pathology 4 
Unable to communicate in English or Welsh 3 
Mental health problems 3 
Current leg pain worse than or as bad as back 
pain 
3 
Previous episode of sciatica in the last six 
months 
2 
Incidental serious pathology identified by MRI 1 
Previous use of biological agents targeting 
TNF-alpha 
1 
Contra-indications to adalimumab 1 
Pregnant or breast-feeding 1 
Reasons for withdrawal and exclusion from 
first clinical assessment to second clinical 
assessment 
17 
Mild symptoms – discharged to GP care 7 
Study closure 5 
Over time limit for second clinical assessment 1 
TB screening failed 1 
Participant revealed long term history of 
widespread pain at screening – particularly in 
shoulders 
1 
No positive neurological test 1 
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Patient did not attend appointment and could 
not be contacted 
1 
Reasons for withdrawal and exclusion from 
six week follow-up to six month follow-up 
4 
Study closure 4 
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Box 1 Ten lessons learnt for consideration in a future trial 
Contracts 1 Early agreement between sponsor, NHS sites and university centres 
about how the contracting process should be arranged with model 
research collaboration agreements 
Site set-up 2 Early discussions about site requirements using a site feasibility 
questionnaire 
 3 Recruitment of a dedicated research physiotherapist (or other 
personnel) at each site 
Treatment 
acceptability 
4 Establish if the proposed treatemt is acceptable to all principal 
investigators 
 5 Determine if the proposed treatment is acceptable to sciatica 
patients, using further qualitative research 
Recruitment 6 Simplify two-stage recruitment process 
 7 Use telephone or text reminders two weeks after patients receive 
letter of invitation 
 8 Use of lay advocates already recruited into the study 
 9 Recruitment during real-time GP consultations 
Feasibility study 10 Feasibility study testing several key recruitment methods  
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Figure 1 Trial Flowchart 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Severe symptoms, referral for MRI and 1st consent 
Failed primary care treatment or referred to local musculoskeletal service 
(>4/52, <6/12 duration, severe symptoms or recurrence), screened for 
eligibility criteria and trial information sent 
Physiotherapy clinical assessment and screening  
Serious spinal pathology 
excluded 
MRI findings used in planned 
sub-group analysis 
Mild symptoms – advice 
Discharge back to GP care 
Remote 
Randomisation 
Adalimumab injection 80mg then 
40mg after 2 weeks  
(sub-cutaneous) (n=166) 
Concurrent physiotherapy 
intervention 
Placebo injection repeated after 2 
weeks (n=166) 
Concurrent physiotherapy 
intervention 
MRI scan, TB screening, biological agent 
counselling, blood and urine tests 
Postal outcome measures at 6 weeks  
Symptoms settled 
Discharge back to GP care 
Symptoms persist 
Further treatment planned with MRI 
results 
Semi-structured telephone interviews at 12 months (n=266) 
Postal outcome measures at 6 months  
2nd clinical assessment, 2nd consent, baseline 
outcome measurement (n=332) 
Postal outcome measures at 12 months (n=266) 
Telephone contact by research physiotherapist to determine potential 
eligibility. If so appointment given for research physiotherapy clinic 
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Figure 2 Trial timetable 
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Figure 3 Participant flow diagram for NHS sites A, B, D and E 
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